Odronextamab Monotherapy Shows Encouraging Efficacy, Manageable Safety for DLBCL Progressing After CAR-T Therapy
According to a primary analysis from the ELM-1 study, CD20-CD3 bispecific antibody odronextamab demonstrated encouraging efficacy and manageable safety among patients with relapsed/refractory DLBCL progressing after CAR T-cell therapy.
These results were presented by Matthew Matasar, MD, MS, Division of Blood Disorders, Rutgers Cancer Institute and RWJBarnabas Health, New Brunswick, New Jersey, at the 66th ASH Annual Meeting in San Diego, California.
“Odronextamab monotherapy was associated with encouraging efficacy and generally manageable safety in a setting with limited treatment options and historically dismal outcomes,” wrote Matasar and colleagues.
“Efficacy was observed even in patients relapsing in ≤90 days, supporting the potential of odronextamab as an accessible, off-the-shelf option in the post-CAR-T setting,” they added.
Source:
Matasar M, Topp S, Allan J, et al. Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study. Presented at the 66th ASH Annual Meeting & Exposition; December 7-10, 2024; San Diego, California. Abstract 866.
